Introduction {#Sec1}
============

The FMS-like tyrosine kinase-3 (FLT3) is expressed by myeloid and lymphoid progenitors, and it is responsible for differentiation, proliferation, and apoptosis of the cells. Internal tandem duplication in the juxtamembrane domain of FLT3 (FLT3/ITD) is frequent molecular aberration which is detected in approximately 30% of the patients with acute myeloid leukemia and normal diploid karyotype (AML-CN). This mutation leads to ligand-independent activation of the receptor and its signaling pathways \[[@CR1]\]. Many studies have demonstrated that the occurrence of *FLT3/ITD* mutation in AML remains a poor prognostic factor owing for high relapse rate and shortened survival \[[@CR2], [@CR3]\]. However, it was recently shown that this aberration produces a negative effect only if the ratio of mutated to normal alleles is \> 0.5 \[[@CR4]\].

The role of allogeneic stem cell transplantation (Allo-SCT) in FLT3*-*mutated patients in the first complete remission (CR1) seems to be controversial, especially in the view of the newest findings in the molecular signature of AML. The assessment of *FLT3/ITD* allelic ratio and co-occurrence of NPM1 mutation have a confirmed impact on risk stratification and therapeutic approaches \[[@CR4]--[@CR6]\]. The results from the donor versus no donor study of adult patients with *FLT3/ITD* mutation treated according to the United Kingdom Medical Research Council (UK MRC) AML protocol have demonstrated lower relapse rate for patients with donor, but no difference in overall survivals (OS) between compared groups \[[@CR7]\]. It was also found that FLT3-mutated patients when compared with FLT3-unmutated had higher relapse incidence (RI) and lower leukemia-free survival (LFS) even after Allo-SCT. Nevertheless, more than 50% of the transplanted patients carrying this mutation were leukemia free at 2 years. Of note is that other predictors than *FLT3/ITD* mutation may play a role in leukemia relapse after transplantation \[[@CR8]\]. The *FLT3/ITD* mutation may serve as a marker of minimal residual disease (MRD), and its utility has been evaluated in a single study so far \[[@CR9]\].

The aim of the study was to evaluate the potential factors which may have an impact on a post-transplant outcome in FLT3-mutated patients with AML following Allo-SCT.

Material and methods {#Sec2}
====================

The study patients were retrospectively identified through the use of our institutional database of medical records. The diagnosis of AML and response criteria to therapy were based on European Leukemia Net Recommendations \[[@CR4]\]. Marrow aplasia (MA) was defined as pancytopenia with bone marrow aplasia after salvage chemotherapy. Patients were treated according to Polish Adult Leukemia Group (PALG) protocol \[[www.palg.witaj.pl](http://www.palg.witaj.pl)\] and induction chemotherapy included DA+/− C regimen (daunorubicin, cytarabine, cladribine). For those who achieved complete remission, 2 cycles of consolidative chemotherapy consisting of mitoxantrone with cytarabine (HAM) or cytarabine alone (ARA-C) were administered. For patients with resistant disease (RD) after 2 inductions, 3 different salvage regimens were given according to the treating physician: CLAM (cladribine, cytarabine, mitoxantrone), MEC (mitoxantrone, etoposide, cytarabine), and FLAG-IDA (fludarabine, cytarabine, idarubicin, G-CSF). All patients who were FLT3-mutated at diagnosis were proceeded to Allo-SCT according to the center policy.

The *FLT3/ITD* and nucleophosmin (NPM1) mutation analysis were performed at diagnosis, and FLT3/ITD was then performed before conditioning commencement and at day + 30 after procedure. Multiplex fluorescence-based PCR method was performed on DNA isolated from bone marrow aspirate sample as described elsewhere. The sensitivity of this assay is approximately 5% \[[@CR10]\]. All patients were grouped according to the molecular and cytogenetic genetic stratification of the European Leukemia Net (ELN) 2010 \[[@CR11]\] as most AML patients (38/43) were diagnosed \< 2017. Data on *FLT3/ITD* allelic ratio was available only for 4 patients, and therefore this parameter was not analyzed. Chimerism of unseparated blood leukocytes was assessed by a short tandem repeat polymerase chain reaction.

Statistics {#Sec3}
----------

Time to event was assessed from the day of transplantation. Nonparametric comparisons of group means were performed by using the Mann-Whitney *U* test. Proportions were compared by Fisher exact test. The Kruskal-Wallis test was used to compare more than two independent groups of variables. Non-relapse mortality (NRM) was defined as all deaths before disease recurrence. The distribution for overall survival (OS) and leukemia-free survival (LFS) was estimated using the method of Kaplan and Meier and compared using the log-rank test. A *p* value less than 0.05 was considered significant. Proportional hazards models (Cox regression) were fitted to investigate effects of prognostic factors for OS.A Spearman's rank test was used to assess the correlation between variables. All computations were performed with StatSoft Poland analysis software (version 10.0).

Results {#Sec4}
=======

Patient characteristics {#Sec5}
-----------------------

Forty-three patients (28 females and 15 males) with AML at median age of 45 years (range 19--67) underwent Allo-SCT between 2009 and 2019. Four patients were ≥ 60 years at transplant and 3 had prior myelodysplastic syndrome. All patients demonstrated detectable *FLT3/ITD* mutation by polymerase chain reaction (PCR). Sixty percent of the subjects had normal diploid karyotype, and trisomy 8 was the most common cytogenetic abnormality (*n* = 4). Study patients were stratified into the following risk groups: 2 patients were categorized to adverse risk group as they had monosomies of chromosomes 5 and 7; 4 patients were in intermediate-2 group as they had cytogenetic abnormalities not classified as favorable or adverse; and 30 patients were in intermediate-1 group, and in 7 patients, no metaphases were obtained (they were stratified to intermediate-1 category based on molecular status only).

Induction regimen consisted of DAC (*n* = 30) or DA (*n* = 13). No induction death was observed. Thirty patients (70%) achieved the first complete remission (CR1), and CR2 was demonstrated in 4 after re-induction. Nine subjects developed irreversible marrow aplasia after chemotherapy.

Hematological status at transplant was as follows: CR1 in 29 patients, CR2 in 5, and 9 patients were transplanted in MA. Twenty-seven patients had FLT3 MRD negativity before procedure. Median time from diagnosis to transplant was 16.7 months (range 5.1--76). Patients' characteristics are shown in Table [1](#Tab1){ref-type="table"}.Table 1Patients characteristicsVariable*n* = 43  Gender (female/male)28/15  Age, years; median, range45 (19--67)  Hemoglobin level (g/dl); median, range8.8 (5.7--13.0)  Leukocyte count (× 10^9^/l); median, range47.5 (1.7--197.0)  Platelet count (× 10^9^/l); median, range66 (5--148)  Blasts in blood (%); median, range79 (11--100)  Blasts in bone marrow (%); median, range87 (24--100)  Splenomegaly, *n*; %12 (28)  Hepatomegaly, *n*; %7 (16)  Lymphadenopathy, *n*; %11 (25)FAB subtype  M1  M2  M4  M5715183Karyotype, *n*; %  diploid  + 8  − 5q  + 11  inv9  −  7q  t(1;7)  + 3,+ 13  no metaphases26 (60)4 (9)1 (2)1 (2)1 (2)1 (2)1 (2)1 (2)7 (19)Prior MDS, *n*; %3 (7)Hematologic response at transplant, *n*; %  First or second complete remission  Marrow aplasia34 (79)9 (21)FLT3/ITD mutation at transplant, *n*; %  Negative  Positive27 (63)16 (27)Time from diagnosis to transplant in months; median, range16.7 (5.1--76.0)

Transplant data {#Sec6}
---------------

### Baseline characteristics of the transplanted patients {#Sec7}

Twelve patients were transplanted from HLA-matched sibling, and 30 patients received either 10/10 HLA-matched unrelated donor (*n* = 22) or 9/10 HLA-mismatched grafts (*n* = 8). One patient underwent haploidentical transplantation from sister. Peripheral blood was a source of stem cells for all transplanted patients. In total, 26 patients received myeloablative conditioning (MAC), whereas reduced-intensity conditioning (RIC) was provided for 17 subjects. MAC consisted of busulfan and cyclophosphamide (BuCy), and fludarabine-based regimens were given as RIC. Anti-thymocyte globulin (ATG) was administered for all patients who had received a graft from the unrelated donors. Graft versus host disease (GHVD) prophylaxis included cyclosporine and methotrexate in all but one patient with haploidentical transplantation who received cyclosporine with mycophenolate mofetil and post-transplant cyclophosphamide.

### Outcome of the transplanted patients {#Sec8}

There were no primary graft failures (PGF). Median time from transplantation to acute graft versus host disease (GVHD) was 17 days (range 7--106). Acute and chronic GVHD developed in 58% and 14% of patients, respectively. Acute GVHD grade III/IV was present in 6 patients. Two patients had limited and 4 extensive chronic GVHD.

Twelve patients demonstrated mucositis grade 3 or 4 after transplantation. No other severe infectious complications were demonstrated. Two subjects developed post-cyclophosphamide hemorrhagic cystitis, one patient had veno-occlusive disease and one had acute renal failure. Six patients had CMV reactivation prior to day + 30. No patients died within the first 30 days, whereas 6 patients expired prior to day + 100 after transplantation: 3 due to early leukemia progression and subsequent chemo-resistance, 2 as a consequence of steroid-resistant acute GVHD, and 1 patient for aspergillosis.

Post-allograft CR rate amounted to 88% including 4 patients who were transplanted in MA and converted to CR. Five patients who were transplanted in MA had leukemia progression. In total, among 9 patients transplanted in MA, 4 patients were alive at last contact. Twenty-eight (65%) patients achieved *FLT3/ITD* negativity at day + 30 after Allo-SCT, and 21 of them are still alive. In contrast, only 1 patient is alive among those who were FLT3-mutated at day + 30. Non-relapse mortality (NRM) at 2 years was 7%.

In total, 17 patients relapsed after median of 4.8 months (range 0.9--27.4) following transplantation. We look at different variables which may have an impact on the incidence of relapse. The following factors were analyzed: hematological status at transplant, donor source, type of conditioning, the occurrence of acute GVHD, and the presence of *FLT3/ITD* mutation at transplantation and at day + 30 after procedure. The relapse incidence (RI) was lower for patients who were FLT3 MRD negative at transplant when compared with those who remained FLT3 MRD positive (41% vs 59%; *r* = 0.36; *p* = 0.01). The patients who eradicated *FLT3/ITD* mutation at day + 30 post-transplantation had significantly lower RI than those who had detectable *FLT3/ITD* (23% vs 76%; *r* = 0.7; *p* \< 0.001). No other correlations were found. Five patients who were FLT3-mutated at transplant eradicated this mutation after allografting. Four patients are alive and remain in CR, and one patient died due to severe GVHD with subsequent infectious complications. Of note is that the latter one had no features of leukemia relapse. Moreover, a strong positive correlation between the post-transplant *FLT3/ITD* status and survival was demonstrated (*r* = 0.65; *p* \< 0.001).

NPM1 mutation at diagnosis was tested in 22 AML patients and was detectable in 10 (45%). There were 7 post-transplant relapses in FLT3 MRD(+)/NPM(+) group, and 2 subjects had leukemia recurrence in FLT3 MRD(+)/NPM(−) group (*p* = 0.62). There was one leukemia recurrence in FLT3 MRD(−)/NPM(−) group.

Data on MRD measured by flow cytometry (MRD-FC) at transplant were available in 28 patients, and positive results were demonstrated in 21. There was a strong positive correlation between FLT3 MRD(+) and MRD-FC(+) (*r* = 0.53; *p* = 0.03).

There were 8/13 (62%) post-transplant leukemia relapses in patients who were FLT3 MRD(+)/MRD-FC(+), 2/8 (25%) relapses in FLT3 MRD(−)/MRD-FC (+,) group and 1/7 (14%) disease recurrence in those who had FLT3 MRD(+)/MRD-FC(−).

At the last follow-up, 21 (49%) patients died. The main causes of death included disease progression (*n* = 15), infectious complications (*n* = 2), and steroid-resistant GVHD (*n* = 2). In 2 cases, the cause of death remained unknown. In total, there were 18 (86%) deaths within the first 2 years after transplant.

Twenty-wo patients (51%) are alive at the last contact, and 21 remain in hematological and molecular CR. All those patients had full donor chimerism. One patient had leukemia relapse and received salvage chemotherapy. Median follow-up from diagnosis and from transplantation was 2.1 years (range 0.6--10.9) and 15 months (range 1--119), respectively. Median follow-up for those who are alive after procedure is 34.1 month (range 1.0--119.6). Transplant data are summarized in Table [2](#Tab2){ref-type="table"}.Table 2Transplant dataVariable*n* = 43Type of donor, *n*;%  Related  10/10-HLA matched unrelated  9/10-HLA-matched unrelated  haploidentical12 (28)22 (51)8 (19)1 (2)Myeloablative conditioning, *n*; %26 (60)Conditioning regimen, n; %  Busulfan/cyclophosphamide  Treosulfan/fludarabine  Busulfan/fludarabine  Fludarabine/TBI26 (60)10 (23)3 (7)4 (10)Number of transplanted CD34-positive cells (× 10^6^/kg); median, range5.4 (3.1--20.4)ANC \> 0.5 (× 10^9^/L); median, range16 (11--29)PLT \> 20 (× 10^9^/L); median, range15 (10--32)Acute GVHD, n; %12 (58)Acute GVHD III/IV, n; %6 (14)Chronic GVHD, n; %6 (14)Hematologic relapse, n; %17 (39)Alive at last contact, n; %22 (51)FLT3/ITD mutation at day + 30, *n*; %  Negative  Positive28 (65)15 (35)Median follow-up from transplantation, months; median, range15 (1--119)*ANC* absolute neutrophil count; *GVHD* graft versus host disease; *PLT* platelet count; *TBI* total body irradiation

Patients who relapsed after transplantation received a variety of salvage treatments depending on whether they were fit or frail. In total, 11 patients were eligible for intensive chemotherapy and they received CLAM (*n* = 4), COAP (cyclophosphamide, vincristine, cytarabine, prednisone; *n* = 3), high-dose cytarabine (*n* = 2), DAC (*n* = 1), and multi-kinase inhibitor---lestaurtinib (*n* = 1). Two patients underwent second allogeneic transplantation following intensive chemotherapy. Six patients received palliative treatments which are the following: hydroxyurea (*n* = 3) and low-doses cytarabine (*n* = 3). None of the patients received midostaurin and any other FLT3-inhibitor as maintenance.

The 2-year LFS and OS were 53% and 54%, respectively. Figures [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}.Median OS from diagnosis and from Allo-SCT were 3.2 years and 28 months. Median LFS after Allo-SCT was 27 months. There was no statistical difference in OS between patients transplanted in CR1/2 and MA. Estimated OS at 2 years were 59% and 33%; (*p* = 0.17), respectively. In univariate analysis, unrelated donor, undetectable FLT3/ITD mutation, and normal liver size before transplant were found to influence LFS; however, only FLT3 status remained significance in multivariate analysis (HR 5.3 95%CI 1.97--14.2); *p* \< 0.001). The following factors influenced the OS in multivariate analysis: type of donor and mutational status. Details are presented in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}.Fig. 1Overall survival for FLT3-mutated AML patientsFig. 2Leukemia-free survival for FLT3-mutated AML patientsTable 3Univariate and multivariate analysis of risk factors for overall survivalUnivariate analysis (log rank)Multivariate analysis (Cox regression)Risk factorOS at 2 years*P* valueHR (95% CI)*P* value*Type of donor*Related *n*=1219%0.010.35 (0.12-1.0)0.05Unrelated *n*=3168%*FLT3/ITD status at transplant*Negative *n*=2774%0.0012.67 (0.94-7.56)0.06Positive *n*=1621%Table 4Univariate and multivariate analysis of risk factors for leukemia-free survivalUnivariate analysis (log rank)Multivariate analysis (Cox regression)Risk factorLFS at 2 years*P* valueHR (95%CI)*P* value*FLT3/ITD status at transplant*Negative *n*=2774%0.0015.3 (1.97-14.2)\< 0.001Positive *n*=1625%*Type of donor*Unrelated *n*=3167%0.02-Related *n*=1228%*Hepatomegaly at diagnosis*No *n*=3661%0.09-Yes *n*=738%

Discussion {#Sec9}
==========

Beneficial role of Allo-SCT in FLT3-mutated AML patients in CR1 remains unclear as these patients had poor prognosis even after procedure. Of note is that the presented data are limited by selection bias and the small number of included patients \[[@CR7], [@CR8]\]. To light up this controversy, a systemic review of 9 studies with 772 FLT3-mutated AML patients has been performed. This meta-analysis has demonstrated that SCT (autologous and allogeneic were lumped together) when compared with chemotherapy alone reduced the relapse rate and prolonged OS and LFS. Unexpectedly, there was no advantage of Allo-SCT over Auto-SCT in terms of OS and LFS, and this probably resulted from the higher transplant-related mortality and lower relapse rate (RR) for patients who received allograft. Higher RR for auto-transplanted patients should be explained by no "graft *versus* leukemia" effect. An interesting observation is that some FLT3-mutated AML patients with no suitable donor may benefit from the Auto-SCT. Of note is that these conclusions were based on 3 studies only, and the results were limited by selection bias, the number of included patients, and inclusion of retrospective and non-randomized studies \[[@CR12]\] (Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}).Fig. 3Overall survival depending on FLT3 MRD status at transplantFig. 4Overall survival depending on donor source

In contrast, there are several studies showing that Allo-SCT improves outcome in FLT3-mutated AML when performed in CR1. The median LFS in FLT3/ITD-transplanted AML population was 54.1 month when compared with 8.6 months for FLT3/ITD-non-transplanted group (*p* = 0.03) \[[@CR13]\]. The comparable parameters for our cohort were 27 and 3 months, respectively \[data not published\].The FLT3-mutated patients who received Allo-SCT as consolidation at CR1 had longer OS and relapse-free survival (RFS) than patients left on chemotherapy alone. OS at 3 year were 54% and 24%, respectively. Multivariate analysis showed the advantage of Allo-SCT over chemotherapy irrespective of *FLT3/ITD* allelic ratio \[[@CR14]\]. The results of transplantation for FLT3-mutated AML beyond CR1 are less encouraging. The post-transplant outcome of 200 FLT3-mutated AML patients was presented by MD Anderson Group. The patients were transplanted both in CR1 and beyond, including those with active disease. Median follow-up was 27 months, and OS and LFS for the entire study cohort at 2 years were 43% and 41%, respectively. RR was the lowest for those who were transplanted in CR1/CR2 and with FLT3 MRD negativity. The worst outcome was demonstrated for patients transplanted in active disease; 85% of them had relapse. In multivariate analysis, hematological/morphological remission and undetectable FLT3 MRD at transplant were found to improve outcome \[[@CR9]\].

Median follow-up for our cohort was 15 months, and OS and LFS at 2 years were found to be slightly better than those reported in Gaballa study \[[@CR9]\]---54% and 53%, respectively. Of note is that disease status had no impact on the post-transplant outcome. OS at 2 years did not differ between patients transplanted in CR1/2 or MA: 59% and 33%, respectively. Patients who had pre-transplant CR1/2 and FLT3 MRD negativity had the excellent 2-year OS (80%). We have also demonstrated that FLT3 MRD negativity is a strong predictor of OS and LFS in multivariate analysis. The 2-year OS for FLT3 MRD negative and FLT3 MRD positive groups at transplant was 74% and 21%, respectively. Our results strongly suggest that pre-transplant detection of *FLT3/ITD* mutation by PCR may serve as a reliable MRD marker which predicts post-transplant outcome better than the hematological disease status. Data on the influence of pre-transplant *FLT3/ITD* status on outcome after allogeneic transplantation are scarce and actually limited to Gaballa study \[[@CR9]\]. Our results are in line with this report, despite lower number of recruited patients. Nevertheless, further studies with larger number of patients are needed to draw final conclusions.

In contrary to previously mentioned report \[[@CR9]\], it was demonstrated that *FLT3/ITD* mutation may occur at any time during leukemia course, and this mutation should not be used as MRD marker in AML \[[@CR15]\]. The introduction of more advanced PCR techniques may increase the sensitivity of PCR method and therefore early therapeutic intervention \[[@CR16]\]. Moreover, it would be valuable to correlate different MRD methods which are the following: PCR assay for FLT3/ITD and multi-parameter flow cytometry (FC).The results of MRD by flow cytometry (MRD-FC) at transplant were available in 28 patients from our cohort, and MRD-FC was positive in 21. There was a strong positive correlation between pre-transplant FLT3 MRD(+) and MRD-FC(+). Data on the role of pre-transplant MRD measured by FC in FLT3-mutated patients have been published recently. Only MRD-FC-positive patients transplanted from HLA-matched sibling donor were found to have poor outcome when compared with MRD-FC-negative transplants from both sibling and haploidentical donors. Interestingly, the outcome of haplo-SCT for MRD-FC-positive patients was comparable with that demonstrated for subjects with pre-transplant MRD-FC-negativity \[[@CR17]\]. In the light of the recent findings and when confirmed in prospective studies, it seems reasonable to consider FLT3 inhibitor as a part of induction therapy and post-transplant maintenance \[[@CR18], [@CR19]\]. A double-blind randomized study showed that the addition of midostaurin to standard chemotherapy significantly improved overall and event-free survival in FLT3-positive AML patients; however, midostaurin was not beneficial as maintenance treatment after transplantation \[[@CR18]\]. In the phase II RADIUS study, FLT3-positive AML patients who underwent Allo-SCT in CR1 were randomized to receive standard of care (SOC) with or without midostaurin. No differences in relapse-free survivals (RFS) between arms at 18 months and 24 months post-transplantation were demonstrated \[[@CR20]\]. In contrast, post-transplant sorafenib improved RFS and OS when compared with placebo in the SORMAIN trial \[[@CR21]\].

Returning to our cohort, patients who received a graft from unrelated donor fared much better than those transplanted from sibling. The latter stands in contrast with Gaballa study \[[@CR9]\], in which unrelated donor was a predictor of worse outcome (LFS/NRM). Our findings are difficult to explain, especially in the context of recent studies which showed the comparable results of Allo-SCT irrespective of donor source \[[@CR22]\]. There was no impact of pre-transplant conditioning on the results of transplantation for FLT3-mutated AML, both in MD Anderson \[[@CR9]\] and in our study; however, other groups found MAC to be more effective than RIC in terms of LFS \[[@CR23]\]. It was also demonstrated that older age (\> 60 years) was not associated with the worse outcome in FLT3-mutated AML patients undergoing Allo-SCT. This procedure was found to be feasible with RIC, and CR1 at transplant was a predictor of favorable outcome \[[@CR24]\]. There were only 4 elderly patients in our cohort and 3 of them are alive; however, the follow-up is relatively short (11 months).

In conclusion, patients with FLT3-mutated AML should proceed to allogeneic stem cell transplantation as soon as possible in the disease course. Most promising results are associated with the FLT3 MRD eradication before transplantation. Post-transplant maintenance with FLT3 inhibitors may increase survival.
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